Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asthma UK

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris

How does the government plan to reshape the NHS?

Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care

Wilmington Healthcare

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

Innovation Networking Event on the InSite Events™ Platform

A customer story

Impetus Digital

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Impetus Digital

Reimagining Healthcare Using Mobile Health Technologies

Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into...

Impetus Digital

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

Detailed results from the NAVIGATOR trial presented at virtual AAAAI meeting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links